WO2025163522 - CYANOTRIAZOLE COMPOUNDS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/163522
Publication Date
07.08.2025
International Application No.
PCT/IB2025/050982
International Filing Date
29.01.2025
Title **
[English]
CYANOTRIAZOLE COMPOUNDS AND USES THEREOF
[French]
COMPOSÉS DE CYANOTRIAZOLE ET LEURS UTILISATIONS
Applicants **
NOVARTIS AG
Inventors
DAUPHINAIS, Maxime
JIRICEK, Jan
KOESTER, Dennis
MENG, Qingshuo
MILLER, Sarah Louise
RENE, Olivier
SHI, Zhicong
TANG, Haihao
VULIC, Katarina
ZHANG, Lei
Priority Data
63/627,485
31.01.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2373 | |
| EPO | Filing, Examination, Granting | 11482 | |
| Japan | Filing, Examination, Granting | 2327 | |
| South Korea | Filing, Examination, Granting | 2368 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
24,490
Contact Us
Abstract[English]
The present invention provides a compound of Formula (I) or a stereoisomer, enantiomer, enantiomeric mixture or pharmaceutically acceptable salt thereof, wherein the variables are as defined herein. The invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating kinetoplastid diseases.[French]
La présente invention concerne un composé de formule (I) (I) ou un stéréoisomère, un énantiomère, un mélange énantiomère ou un sel pharmaceutiquement acceptable de celui-ci, les variables étant telles que définies dans la description. L'invention concerne en outre des compositions pharmaceutiques comprenant de tels composés et des procédés d'utilisation de tels composés pour le traitement de maladies liées auxs kinétoplastidés.